Codexis - CDXS EV/EBITDA Multiple
The price evolution of Codexis, Inc. (CDXS), where the EV/EBITDA ratio is fixed at 0.00, highlights the success of automating biocatalyst screening using robotics. The business relies on its status as a global expert in enzyme engineering, trusted by the largest chemical conglomerates. However, financial stability depends on the budgets of a limited number of customers and the duration of research and development cycles.
Analytical breakdowns for Codexis, Inc.
- stock price and consensus target price:
- issuer market value details:
- issuer book value statistics:
- company liabilities and liquidity data:
- business earnings and investment ratios data:
CDXS - Net Income|Projected Future Earnings Codexis, Inc.|CDXS - Price to Earnings Multiple|Projected Price to Earnings Codexis|CDXS - Growth-Adjusted P/E Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CDXS|CDXS - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Codexis, Inc.|CDXS - Earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months codexis.com|CDXS - Earnings per share growth this year|Earnings growth forecast for next year Codexis, Inc.
Fundamental company valuation:Codexis Bio CDXS
Fundamental risks for Codexis, Inc. (CDXS) require monitoring through the lens of debt sustainability and operational efficiency. Amid competition with pharma behemoths and the threat of protein synthesis, assessing the real business value is critical. This Enterprise Value to EBITDA ratio for Codexis, Inc. (CDXS) compares total capitalization with earnings before interest, taxes, depreciation, and amortization. A decrease in this value indicates growing issuer reliability, although it signals asset degradation in the event of declining revenue.
Competitors of Codexis, Inc. (CDXS)
tempus.com - Enterprise Value to EBITDA Ratio|QGEN: Enterprise Value to Operating Income Before Depreciation|Ionis Pharmaceuticals - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio repligen.com RGEN|Avidity Biosciences, Inc. (RNA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CRSP - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio WGS|RARE: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple BEAM|Total Company Value to Operating Income Before Depreciation Ratio sarepta.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Twist Bioscience, Inc. TWST|TXG: Enterprise Value to Operating Income Before Depreciation|Intellia - EV/EBITDA Multiple|Stoke Corp (STOK) - Enterprise Value to EBITDA Ratio|BLFS (BioLife Solutions, Inc.) - Enterprise Value to EBITDA Ratio|WVE - Total Company Value to Operating Income Before Depreciation Ratio|MAZE (Maze Therapeutics) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Sionna Therapeutics, Inc. (SION)|EV/EBITDA Multiple PRME|Taysha Corp - Enterprise Value to Operating Income Before Depreciation|uniQure N.V. - Enterprise Value to EBITDA Ratio|MGTX: Enterprise Value to Operating Income Before Depreciation|RGNX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Solid Biosciences Inc SLDB|OCGN: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation PACB|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Benitec Biopharma Inc.|Enterprise Value to Operating Income Before Depreciation DSGN (designtx.com)|EV/EBITDA Multiple RCKT|EV/EBITDA Multiple 4DMT (FDMT)|EV/EBITDA Multiple LXEO (Lexeo Therapeutics, Inc.)|KRRO - Enterprise Value to EBITDA Ratio|EDIT - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA silence-therapeutics.com|PRQR: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation SGMO|NAUT (Nautilus Biotechnology, Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Metagenomi Therapeutics MGX|Enterprise Value to EBITDA Ratio DTIL (Precision BioSciences)|generationbio.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple BOLD (Boundless Bio)|Total Company Value to Operating Income Before Depreciation Ratio Exicure Inc. (XCUR)|IMNN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Phio Pharmaceuticals PHIO|MBIO (mustangbio.com) - Enterprise Value to EBITDA Ratio|TransCode Therapeutics, Inc. - Business Value to Operating Income Before Depreciation|BNGO (Bionano Genomics Inc.) - EV/EBITDA Multiple|Applied DNA Sciences Inc (APDN) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bluebird Bio (BLUE)|immunoprecise.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple OMGA (Omega Therapeutics)|OMIC - Enterprise Value to EBITDA Ratio|RGLS: Enterprise Value to EBITDA Ratio|Total Company Value to Operating Income Before Depreciation Ratio Syros Pharmaceuticals Inc. SYRS|TBIO: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio TRACON Pharmaceuticals, Inc|UBX (Unity Biotechnology) - EV/EBITDA Multiple
